Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Complete Title: Phase 1a/1b Open-Label Study of BBO-8520 in Combination with Pembrolizumab in Subjects with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Trial Phase: I
Investigator: Lei Deng
A first in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer
Keywords:
- Lung Carcinoma, Non-Small-Cell (NSCLC)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.